17 evidence-first reviews in this topic, built on 225 peer-reviewed citations. Null and negative trials are reported alongside the positive ones — that is the point of the format.
Aerobic capacity falls faster with every decade, in people who exercise as well as those who do not — yet controlled trials raise the number in older adults by a few mL/kg/min. Five years…
Where the evidence lands: The decline is real and it accelerates: in the Baltimore cohort it ran from 3%-6% per 10 years in the 20s and 30s to more than 20% per 10 years in the 70s and beyond, in every activity quartile. Training has not been shown to flatten that slope; trained men are measured higher at every age, but only controlled trials speak to what training does to an individual. Pooled trials in sedentary older adults show a net VO2max gain of 3.78 mL/kg/min, largest at 66%-73% of heart rate reserve, 40-50 minutes, 3-4 days a week; head-to-head, intervals came out ahead by 1-2 mL/kg/min. Fitness-mortality findings are associations, and non-response is real.
Most night workers’ clocks never fully adapt, and the trials show they don’t need to: timed light and darkness, a fixed sleep anchor, a short nap, early caffeine and daytime meals…
Where the evidence lands: Fewer than 3% of permanent night workers fully adapt their body clock, but partial realignment is enough to bring night-shift alertness and performance close to daytime levels, and it comes from bright light on the shift, dark glasses on the commute, a fixed dark sleep window, and a 30-minute nap. Melatonin adds about 24 minutes of daytime sleep with no dose-response from 1 to 10 mg; caffeine six hours before sleep still shortens it; eating at night impaired glucose tolerance in three laboratory studies. The long-term cardiovascular and diabetes associations are modest and appear after about five years of exposure.
Lean mass can fall during semaglutide or tirzepatide treatment, but a DXA number is not muscle function—and direct preservation trials are just beginning.
Where the evidence lands: GLP-1-based treatment usually removes much more fat than lean tissue, but absolute lean mass can decline. Track strength and physical function—not DXA alone—and treat exercise and adequate nutrition as important care components whose precise protective effects during semaglutide or tirzepatide therapy are still under study.
A viral longevity lesson says to sleep earlier. The stronger—and less glamorous—case is to protect enough sleep on a schedule your body can keep.
Where the evidence lands: Sleep regularity predicts mortality more strongly than duration in large observational cohorts, but it has not been shown to extend life. Aim for enough sleep and a sustainable schedule; an earlier bedtime is not universally better.
The NMN + resveratrol + pterostilbene stack pairs an NAD+ precursor with sirtuin activators to echo caloric-restriction biology — a coherent rationale built mostly from mechanism and mouse…
Where the evidence lands: The design logic is scientifically literate — fuel NAD+, activate SIRT1 — but the combined stack is untested in humans, and resveratrol's caloric-restriction-mimetic potential appears limited even in mice.
Social media has collapsed careful dose reduction, intermittent maintenance, and unapproved compounded ‘microdoses’ into one seductive idea. Human trials support ongoing treatment for…
Where the evidence lands: Evidence supports ongoing GLP-1 treatment for many people with obesity and suggests that supervised dose reduction can sometimes preserve weight loss. It does not show that tiny compounded doses benefit healthy-weight adults, reduce generalized inflammation, or extend human life.
Mortality benefits begin well below 10,000 steps and the curve often flattens with age. More movement helps, but the exact target is not magic.
Where the evidence lands: Health benefits begin below 10,000 steps and often flatten around 6,000-8,000 in older adults. The best target is a safe, sustainable increase from baseline, not a magic threshold.
Coffee drinkers often have lower mortality in cohorts, including decaf drinkers. Mendelian-randomization results are less decisive, keeping causality and optimal dose uncertain.
Where the evidence lands: Coffee has one of nutrition epidemiology's more consistent favorable associations, but observational evidence does not prove that starting coffee extends life. Tolerance, sleep, preparation, and individual risk still matter.
Short-lived cognitive complaints have been reported, but randomized and observational syntheses do not show that statins cause dementia; some cohorts associate treatment with lower risk.
Where the evidence lands: Statins have not been shown to cause dementia. Population evidence is neutral to reassuring, although new individual symptoms should be evaluated rather than dismissed.
Mouse regeneration experiments and small chemotherapy studies became a universal fasting prescription. Human immune rejuvenation has not been demonstrated.
Where the evidence lands: Prolonged fasting affects nutrient-sensing pathways, but no human trial establishes that 72 hours resets immunity or comprehensively clears damaged cells. The claim is an extrapolation from animal and early translational work.
Sleep-duration studies show a U-shaped mortality curve, but long sleep can be a marker of illness and self-reports cannot define one ideal number for everyone.
Where the evidence lands: Sleep and mortality form a U-shaped observational association, not a precise causal prescription. Quality, regularity, symptoms, and individual need matter alongside duration.
Older cohorts suggested protection, but abstainer bias and genetic studies weaken the causal story. Starting to drink is not a longevity strategy.
Where the evidence lands: The classic alcohol J-curve is vulnerable to former-drinker and healthy-user bias. Genetic studies do not support starting alcohol for cardiovascular protection or longevity.
Self-reported success stories and nutrient calculations cannot establish long-term safety, cardiovascular effects, or lifespan benefit from an all-animal-food diet.
Where the evidence lands: No trial shows that a carnivore diet extends life or prevents chronic disease. Short-term symptom reports are hypothesis-generating, while long-term safety and cardiovascular effects remain unanswered.
Three mechanisms drive the afternoon crash, and only one of them answers to more coffee. An evidence-graded day structure for knowledge workers.
Where the evidence lands: Your afternoon crash is at least three separate problems: attention degrading within a long task, sleep pressure building through the day, and any actual sleep deficit you are carrying. Build the day around that, keep caffeine deliberate and well clear of the hours before bed, and treat naps, light and movement as small helps rather than fixes. Nothing in the supplement aisle in this evidence set beats the schedule itself. If two weeks of a fixed structure changes nothing, stop optimizing and get assessed.
You bought the chair and the standing desk and it still aches. Here is what has trial support in office workers, and what is a waste of money.
Where the evidence lands: The link between sitting and back pain is real but modest and almost entirely cross-sectional, which is why buying furniture did not fix your neck. What has trial support in office workers is unglamorous: about ten minutes of high-intensity neck and shoulder resistance work on most days, walking accumulated toward a real weekly total, and enough consistency to hit roughly seven sessions in ten for three months. Skip the early scan unless you have red flags, and treat saddle numbness or any new bladder or bowel change as an emergency department visit today, not a wait-and-see.
What the loading trials actually show about rebuilding a cranky Achilles, patellar tendon, knee or shoulder after 45, and how long it really takes.
Where the evidence lands: Tendon responds to heavy, slow, progressive load, and it still responds after 50, but on a timescale of months rather than weeks. Pick one loading exercise, run it three times a week, judge it by how you feel the next morning, and give it 12 weeks before you judge it at all. Isometrics and blood flow restriction cuffs are useful tools for keeping you loading when pain or joint tolerance gets in the way, and no supplement in this literature outperforms the training itself.
What the trials actually show about heavy training, protein, supplements and broken sleep in midlife, including the ones that found nothing.
Where the evidence lands: Heavy, supervised, technique-first resistance training around three times a week is the intervention with the best evidence for bone density, strength and function in the postmenopausal women these trials studied, and no supplement in this evidence base replaces it, though none of those trials measured fractures, which is what makes a treatment-range scan a clinician conversation rather than a training problem. Protein and creatine are small modifiers around that training, and calcium or vitamin D supplements did not prevent fractures in the largest pooled analysis of adults not being treated for osteoporosis. Sleep improves with a structured cognitive behavioral program rather than a schedule tweak, and feeling too hot at night is worth treating as a primary variable. Anything here about hormone therapy is reporting from the review papers, not a recommendation.
222 distinct peer-reviewed papers, published 1981–2026, across 136 journals. Each links to its PubMed record; where Magellan has published a full study write-up, that is linked too.
Strong evidence
Across meta-analyses and randomized trials, creatine monohydrate combined with resistance training…
Moderate evidence
Randomized trials of methyl-salicylate/menthol patches and menthol-based topical products show…
Moderate evidence
Meta-analyses of randomized trials show that low-load resistance training with blood flow…
Prefer the interactive version? Open the article feed in the Magellan app →